EHA Global Insight丨Dr. Uwe Platzbecker: Breakthrough Advances in Acute Promyelocytic Leukemia Treatment — Key Findings of the APOLLO Study

EHA Global Insight丨Dr. Uwe Platzbecker: Breakthrough Advances in Acute Promyelocytic Leukemia Treatment — Key Findings of the APOLLO Study

Acute promyelocytic leukemia (APL) is a highly aggressive hematological disease, and its treatment has long been a challenge in the field. Chinese scholars have contributed significantly to global APL treatment with the introduction of the arsenic trioxide (ATO) regimen. Since the publication of the APL0406 study in NEJM in 2013, the combination of all-trans retinoic acid (ATRA) and ATO has replaced ATRA combined with chemotherapy as the standard treatment for low- and intermediate-risk APL patients. However, whether this regimen is suitable for high-risk APL patients remains undetermined due to a lack of randomized controlled trials. At the 29th Annual Meeting of the European Hematology Association (EHA 2024) held from June 13-16, 2024, Dr. Uwe Platzbecker from the Leipzig University in Germany presented key findings from the APOLLO study. This study demonstrated that the combination of ATO and ATRA offers a new treatment strategy for high-risk APL patients, providing valuable insights into the current state of APL treatment and guiding future research directions and clinical practices. Oncology Frontier - Hematology Frontier invited Professor Platzbecker to share the important discoveries and clinical significance of the APOLLO study.
EHA International Perspective | B-Pd Regimen—Professor Meletios A. Dimopoulos Reveals New Options for Second-Line Treatment

EHA International Perspective | B-Pd Regimen—Professor Meletios A. Dimopoulos Reveals New Options for Second-Line Treatment

With the rapid development in the field of hematology, new treatment strategies and breakthrough advancements continue to emerge, offering new hope for patients with hematological malignancies. At the 2024 EHA conference, "Oncology Frontier-Hematology Frontier" had the honor of interviewing Professor Meletios A. Dimopoulos from the School of Medicine, National and Kapodistrian University of Athens School of Medicine, delving into the challenges currently faced in the treatment of hematological malignancies, especially for those patients who are refractory to traditional treatments such as lenalidomide and anti-CD38 monoclonal antibody therapy. Professor Dimopoulos' phase 3 DREAMM-8 study data demonstrated the potential and advantages of the B-Pd combination treatment regimen, providing a new option for second-line treatment.
Does Post-TIPS Hepatic Encephalopathy Increase Mortality in Cirrhotic Patients?

Does Post-TIPS Hepatic Encephalopathy Increase Mortality in Cirrhotic Patients?

Recently, a study by Italian scholar Dr. Silvia Nardelli, published in the Journal of Hepatology, found that even if cirrhotic patients develop overt hepatic encephalopathy (OHE) after undergoing transjugular intrahepatic portosystemic shunt (TIPS) surgery, their mortality rate does not significantly increase. This conclusion challenges previous perceptions of the negative impact of OHE in non-TIPS contexts, offering new hope and management strategies for cirrhotic patients.
Delving into the Details: Dr. Zhanhong Chen & Dr. Rui Ge on First-Line Treatment Options for HER2-Positive Breast Cancer

Delving into the Details: Dr. Zhanhong Chen & Dr. Rui Ge on First-Line Treatment Options for HER2-Positive Breast Cancer

When it comes to the "P" in the THP regimen for HER2-positive breast cancer, do you prefer Pertuzumab or Pyrotinib? At the 2024 Breast Cancer Summer Forum · Northern Salon's "Root Cause" session, Dr. Zhanhong Chen from Zhejiang Cancer Hospital and Dr. Rui Ge from Huadong Hospital Affiliated to Fudan University shared their perspectives. Professor Chen advocated for Pyrotinib, while Professor Ge favored Pertuzumab. After the session, Oncology Frontier invited both experts to elaborate on their viewpoints.
Dr. Wenxing Qin: Advances in Research on Drug Resistance Mechanisms of ADCs in Breast Cancer

Dr. Wenxing Qin: Advances in Research on Drug Resistance Mechanisms of ADCs in Breast Cancer

A century ago, Paul Ehrlich, the father of German immunology, proposed the concept of the "Magic Bullet," which targets toxic drugs to microorganisms or tumor cells. With continuous technological breakthroughs, Antibody-Drug Conjugates (ADCs) have seen explosive approval. These drugs combine specific monoclonal antibodies with highly active cytotoxic drugs via linkers, balancing the specificity of targeted therapies with the efficacy of cytotoxic drugs. ADCs have shown strong activity in anti-tumor therapy due to their unique design and pharmaceutical properties, with significant advantages in targeting specificity and reducing side effects. Particularly in breast cancer, ADCs like T-DXd have brought significant survival benefits to advanced patients, transforming the clinical treatment landscape of breast cancer. Despite their impressive clinical performance, ADCs still face the challenge of treatment resistance. Fully understanding the mechanisms of ADC resistance is clinically significant as it guides the development of subsequent treatment strategies. Oncology Frontier invited Dr. Wenxing Qin from Fudan University Shanghai Cancer Center to systematically review the progress in ADC resistance mechanisms and feasible response strategies.
New Concepts in Regional Treatment of Breast Cancer and Future Outlook by Dr. Yongsheng Wang | 2024 CACA Integrated Breast Cancer Conference

New Concepts in Regional Treatment of Breast Cancer and Future Outlook by Dr. Yongsheng Wang | 2024 CACA Integrated Breast Cancer Conference

At the 2024 China Anti-Cancer Association (CACA) Integrated Breast Cancer Conference, Dr. Yongsheng Wang from Shandong Cancer Hospital elaborated on new concepts in regional treatment for breast cancer. He emphasized that local regional treatment for breast cancer patients should comprehensively consider the risk of recurrence and metastasis, the efficacy and adverse effects of systemic treatment, and the efficacy and adverse effects of local regional management. Professor Wang also proposed a new definition for axillary lymph node negativity and discussed individualized adjuvant radiotherapy strategies for patients with positive sentinel lymph node biopsy and new strategies for managing the internal mammary region. Following the conference, Oncology Frontier invited Professor Wang for an in-depth discussion on regional lymph node treatment.
Comprehensive Review of Chemotherapy-Induced Anemia Management in China (1)

Comprehensive Review of Chemotherapy-Induced Anemia Management in China (1)

Cancer-related anemia (CRA) encompasses anemia that occurs in cancer patients during disease progression or treatment, including non-chemotherapy-related CRA and chemotherapy-induced anemia (CIA). With the increase in chemotherapy treatments, the incidence of anemia is significant, with over 90% of patients not receiving any corrective treatment. To gain a comprehensive understanding of the current practices and perceptions of Chinese clinicians in managing CIA and to improve the management level of CIA in China, Oncology Frontier initiated a "Survey on Chemotherapy-Induced Anemia in Cancer Patients," collecting 308 questionnaires from 28 provinces and cities across the country. The survey revealed that although the current management concepts of CIA in China still differ from existing guidelines, Chinese clinicians' awareness of CIA management is continually strengthening, contributing to the standardization of management for anemia related to new anti-cancer therapies.